MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Daily Archives February 2, 2017

HALT-MS

HALT-MS: Five Year Study Results

MStranslate
February 2, 2017
Research, Stem Cells, Treatments
Research Summary: High dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS The 5 year results of the HALT-MS trial were today published in Neurology.  The HALT-MS clinical trial has...

Recent Posts

  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib

Recent Comments

  • MStranslate on Multiple Sclerosis Research In 2026
  • MStranslate on Multiple Sclerosis Research In 2026
  • K on Multiple Sclerosis Research In 2026
  • Mohammad on Multiple Sclerosis Research In 2026
  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date

Calendar

February 2017
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728  
« Jan   Mar »

Archives

Categories

Posts

  • Assessing & Monitoring Cognition in MS
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.